TrialJournal of cellular and molecular medicine2021

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.

Xinghe Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.